Valeant Pharmaceuticals Intl (TSE:VRX) (NYSE:VRX) will be releasing its earnings data before the market opens on Wednesday, February 28th. Analysts expect Valeant Pharmaceuticals Intl to post earnings of C$1.23 per share for the quarter.

Valeant Pharmaceuticals Intl (TSE:VRX) opened at C$23.48 on Wednesday. The stock has a market cap of $8,180.00, a price-to-earnings ratio of 4.79 and a beta of -0.89. Valeant Pharmaceuticals Intl has a fifty-two week low of C$11.20 and a fifty-two week high of C$30.56.

A number of research firms have issued reports on VRX. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a C$23.00 price target on shares of Valeant Pharmaceuticals Intl in a report on Wednesday, November 8th. TD Securities raised shares of Valeant Pharmaceuticals Intl from a “hold” rating to a “buy” rating and set a C$25.50 price target for the company in a report on Wednesday, November 8th.

ILLEGAL ACTIVITY NOTICE: This piece was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at

Valeant Pharmaceuticals Intl Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Earnings History for Valeant Pharmaceuticals Intl (TSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with's FREE daily email newsletter.